Severe Asthma - Pipeline Insight, 2025
Description
DelveInsight’s, “Severe Asthma - Pipeline Insight, 2025” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Severe Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Severe Asthma: Overview
Asthma is a chronic condition of the lungs that involves inflammation and hyperactivity of the airways. With many symptoms and presentations, asthma can be triggered by breathing allergens from the environment such as pollen, dust, animal dander, mold, or other irritants. Severe asthma is defined as someone diagnosed with asthma requiring medium or high-dose inhaled corticosteroids combined with other longer-acting medications. Asthma is also considered severe when it is uncontrolled despite proper use of these medications. Individuals who suffer from severe uncontrolled asthma experience symptoms throughout most days and every night. These patients often require the frequent use of inhaled medications or even daily oral steroids to provide rescue from their asthma symptoms. Severe asthma may impact daily activities, resulting in missing work or school, and can directly affect a patient’s quality of life. Severe asthma presents with persistent and debilitating symptoms, including recurrent and severe episodes of wheezing, shortness of breath, chest tightness, and coughing, often worsening at night or in the early morning hours. Patients may experience frequent exacerbations despite optimal management, leading to significant limitations in daily activities and a higher risk of hospitalizations. Additionally, severe asthma can manifest as symptoms that are poorly controlled with standard medications.
Severe asthma is characterized by persistent airflow obstruction, chronic airway inflammation, and airway remodeling. The pathophysiology involves increased activation and infiltration of inflammatory cells like eosinophils and mast cells in the airways. This leads to airway hyper responsiveness, mucus hypersecretion, and structural changes like airway smooth muscle hypertrophy and sub epithelial fibrosis. These changes can worsen over time and result in irreversible airflow limitation if not properly managed with appropriate medications like inhaled corticosteroids and bronchodilators.
Patients with severe asthma often demonstrate significant reduction of their lung function when tested by spirometry or a pulmonary function test (PFT). The best option when choosing a physician to manage severe asthma is to contact an allergy / immunology specialist. An allergist / immunologist has the relevant knowledge, training, and skills necessary to properly diagnose and manage asthma. If severe asthma is suspected, differential diagnoses that may mimic asthma should first be ruled out. This requires a detailed clinical history. Computed tomography (CT) of the chest may also be useful, as it can rule out many differential diagnoses (including malformations, dysplasias, tumors, bronchiolitis, bronchiectasis, pulmonary embolism, alveolitis, and various interstitial lung diseases). Allergy testing (skin prick test and/or measurement of allergen-specific IgE antibodies) are part of standard assessment.
Patients with severe asthma often demonstrate significant reduction of their lung function when tested by spirometry or a pulmonary function test (PFT). The best option when choosing a physician to manage severe asthma is to contact an allergy / immunology specialist. An allergist / immunologist has the relevant knowledge, training, and skills necessary to properly diagnose and manage asthma. If severe asthma is suspected, differential diagnoses that may mimic asthma should first be ruled out.
""Severe Asthma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Asthma pipeline landscape is provided which includes the disease overview and Severe Asthma treatment guidelines. The assessment part of the report embraces, in depth Severe Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Severe Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Severe Asthma Emerging Drugs
Further product details are provided in the report……..
Severe Asthma: Therapeutic Assessment
This segment of the report provides insights about the different Severe Asthma drugs segregated based on following parameters that define the scope of the report, such as:
Severe Asthma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Severe Asthma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Asthma drugs.
Severe Asthma Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Severe Asthma: Overview
Asthma is a chronic condition of the lungs that involves inflammation and hyperactivity of the airways. With many symptoms and presentations, asthma can be triggered by breathing allergens from the environment such as pollen, dust, animal dander, mold, or other irritants. Severe asthma is defined as someone diagnosed with asthma requiring medium or high-dose inhaled corticosteroids combined with other longer-acting medications. Asthma is also considered severe when it is uncontrolled despite proper use of these medications. Individuals who suffer from severe uncontrolled asthma experience symptoms throughout most days and every night. These patients often require the frequent use of inhaled medications or even daily oral steroids to provide rescue from their asthma symptoms. Severe asthma may impact daily activities, resulting in missing work or school, and can directly affect a patient’s quality of life. Severe asthma presents with persistent and debilitating symptoms, including recurrent and severe episodes of wheezing, shortness of breath, chest tightness, and coughing, often worsening at night or in the early morning hours. Patients may experience frequent exacerbations despite optimal management, leading to significant limitations in daily activities and a higher risk of hospitalizations. Additionally, severe asthma can manifest as symptoms that are poorly controlled with standard medications.
Severe asthma is characterized by persistent airflow obstruction, chronic airway inflammation, and airway remodeling. The pathophysiology involves increased activation and infiltration of inflammatory cells like eosinophils and mast cells in the airways. This leads to airway hyper responsiveness, mucus hypersecretion, and structural changes like airway smooth muscle hypertrophy and sub epithelial fibrosis. These changes can worsen over time and result in irreversible airflow limitation if not properly managed with appropriate medications like inhaled corticosteroids and bronchodilators.
Patients with severe asthma often demonstrate significant reduction of their lung function when tested by spirometry or a pulmonary function test (PFT). The best option when choosing a physician to manage severe asthma is to contact an allergy / immunology specialist. An allergist / immunologist has the relevant knowledge, training, and skills necessary to properly diagnose and manage asthma. If severe asthma is suspected, differential diagnoses that may mimic asthma should first be ruled out. This requires a detailed clinical history. Computed tomography (CT) of the chest may also be useful, as it can rule out many differential diagnoses (including malformations, dysplasias, tumors, bronchiolitis, bronchiectasis, pulmonary embolism, alveolitis, and various interstitial lung diseases). Allergy testing (skin prick test and/or measurement of allergen-specific IgE antibodies) are part of standard assessment.
Patients with severe asthma often demonstrate significant reduction of their lung function when tested by spirometry or a pulmonary function test (PFT). The best option when choosing a physician to manage severe asthma is to contact an allergy / immunology specialist. An allergist / immunologist has the relevant knowledge, training, and skills necessary to properly diagnose and manage asthma. If severe asthma is suspected, differential diagnoses that may mimic asthma should first be ruled out.
""Severe Asthma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Asthma pipeline landscape is provided which includes the disease overview and Severe Asthma treatment guidelines. The assessment part of the report embraces, in depth Severe Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Severe Asthma R&D. The therapies under development are focused on novel approaches to treat/improve Severe Asthma.
This segment of the Severe Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Severe Asthma Emerging Drugs
- GSK3511294: GlaxoSmithKline
- BSI-045B: Biosion
- FB704A: Oneness Biotech
- KN-002: Kinaset Therapeutics
Further product details are provided in the report……..
Severe Asthma: Therapeutic Assessment
This segment of the report provides insights about the different Severe Asthma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Severe Asthma
- There are approx. 40+ key companies which are developing the therapies for Severe Asthma. The companies which have their Severe Asthma drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Severe Asthma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Severe Asthma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Asthma drugs.
Severe Asthma Report Insights
- Severe Asthma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Severe Asthma drugs?
- How many Severe Asthma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Severe Asthma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Severe Asthma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Severe Asthma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kinaset Therapeutics
- Bio-Thera Solutions
- CSPC ZhongQi Pharmaceutical Technology
- AB Science
- GlaxoSmithKline
- Oneness Biotech
- Biosion
- Lanier Biotherapeutics
- Kymera Therapeutics
- Suzhou Connect Biopharmaceuticals
- Upstream Bio
- Teva Branded Pharmaceutical Industries
- KN-002
- BAT2606
- CM326
- Masitinib
- GSK3511294
- FB 704A
- BSI-045B
- LNR 125.38
- KT 621
- CBP-201
- Verekitug
- TEV248
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Severe Asthma: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Severe Asthma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- GSK3511294: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- BSI-045B: Biosion
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- KN-002: Kinaset Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Severe Asthma Key Companies
- Severe Asthma Key Products
- Severe Asthma- Unmet Needs
- Severe Asthma- Market Drivers and Barriers
- Severe Asthma- Future Perspectives and Conclusion
- Severe Asthma Analyst Views
- Severe Asthma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
